Full-Time

Senior Product Director

Enterprise AI R&D

Updated on 9/10/2026

GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

No salary listed

No H1B Sponsorship

Waukesha, WI, USA

In Person

Bachelor's, Master's

Category
Product (1)
Required Skills
LLM
Product Management
Machine Learning
RAG
Cybersecurity

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • A bachelor's or advanced degree in engineering, computer science, or a related technical field is required.
  • At least 12 years of industry experience, including at least 6 years leading complex cross-functional initiatives, is required.
  • Expertise in artificial intelligence and machine learning technologies, including large language models, retrieval-augmented generation, validation methods, and responsible artificial intelligence practices, is required.
  • Strong understanding of regulated research and development processes, Design Controls, and Quality Management Systems is required.
  • Proven success in product management, program leadership, or technical portfolio governance is required.
  • Experience quantifying business value, defining return on investment, and driving measurable outcomes is required.
Responsibilities
  • Own and maintain the enterprise roadmap for artificial intelligence in Research and Development and Quality, aligning it with the company’s AI Big Bets and communicating strategic direction, progress, objectives, and outcomes.
  • Monitor artificial intelligence, regulatory, and industry trends to guide prioritization and strategic investment, anticipate change, mitigate risk, and identify emerging opportunities.
  • Partner with Quality, Segments, STO, and Information Technology to define scope, benefits, and requirements for enterprise priority initiatives and ensure investments are appropriately aligned and resourced.
  • Translate business and engineering needs into clear definitions of value, scope, requirements, and readiness criteria.
  • Define and maintain readiness criteria for artificial intelligence tools in alignment with validation, governance, and Quality Management System expectations.
  • Drive measurable productivity gains and earnings-before-interest-and-taxes impact through disciplined sequencing of artificial intelligence use cases.
  • Engage champion segments to pilot, refine, adopt, and scale validated artificial intelligence solutions, securing operational sponsorship and reducing risk before broader enterprise deployment.
  • Communicate consistently upward, downward, and across the organization to maintain alignment, transparency, and momentum.
  • Maintain a healthy funnel of new artificial intelligence use-case opportunities by identifying, assessing, and prioritizing opportunities across the enterprise.
  • Ensure compliance with Responsible AI, cybersecurity, privacy, and GxP validation frameworks to safeguard product quality and patient safety.
  • Communicate benefit realization, adoption progress, and risk mitigation to executive stakeholders and help leadership prioritize resources toward high-value initiatives.
Desired Qualifications
  • Exceptional communication, storytelling, and executive influence skills.
  • Experience designing or deploying enterprise artificial intelligence platforms or complex digital ecosystems.
  • A strong systems-thinking approach with the ability to model workflows and identify artificial intelligence leverage points.
  • Ability to lead through ambiguity and build alignment across distributed teams.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Photonova Spectra won CE Mark on August 31, 2026, opening Europe sales.
  • Q2 2026 orders rose 11.1%, with 1.15x book-to-bill and record backlog.
  • Vivid cardiovascular ultrasound and ABUS breast screening launches broaden 2026 revenue opportunities.

What critics are saying

  • Patient Care Solutions revenue fell 13.5% in Q2 2026; management is reviewing a sale.
  • Jay Saccaro left in August 2026; William Grogan starts September 14, 2026.
  • If PCS recovery slips into 2027, GE HealthCare becomes a slower-growth imaging vendor.

What makes GE Healthcare unique

  • Photonova Spectra’s Deep Silicon CT differentiates GE HealthCare with photon-counting imaging.
  • GE HealthCare spans imaging, pharma diagnostics, ultrasound, and monitoring across hospital workflows.
  • The July 2026 backlog of $23.9 billion reflects sticky installed-base demand and services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Sep 1st, 2026
GE HealthCare secures CE mark for Photonova Spectra photon-counting CT system

GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.

Yahoo Finance
Aug 31st, 2026
Vertex Pharmaceuticals shows promise while GE HealthCare and Wells Fargo face challenges

Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.

Associated Press
Aug 28th, 2026
GE HealthCare launches three new Vivid cardiovascular ultrasound systems for diverse care settings

GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.